Can I Take 5-HTP with Rezdiffra (Resmetirom)?

What Is Resmetirom and How Does It Work?

Resmetirom (brand name Rezdiffra) is a selective thyroid hormone receptor beta (THR-beta) agonist approved by the FDA in March 2024. It is the first drug approved specifically to treat non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with stage F2 or F3 fibrosis [1]. It works by activating THR-beta receptors predominantly in the liver, reducing lipid synthesis, improving mitochondrial function, and decreasing hepatic fat content without the cardiovascular and bone side effects associated with systemic thyroid hormone excess [2].

The MAESTRO-NASH Trial

The approval rested on data from MAESTRO-NASH (N=966), a 52-week randomized, double-blind, placebo-controlled trial. At the 120 mg dose, 25.9% of resmetirom patients achieved MASH resolution without worsening fibrosis versus 14.2% on placebo (P<0.001) [3]. Fibrosis improvement of at least one stage occurred in 26% of the 120 mg group versus 14% placebo (P<0.001) [3].

Metabolic and Pharmacokinetic Profile

Resmetirom is primarily metabolized by CYP2C8 and, to a lesser extent, CYP3A4. It is also a substrate of the hepatic uptake transporters OATP1B1 and OATP1B3 [4]. Co-administration with strong CYP2C8 inhibitors or OATP1B inhibitors can meaningfully raise resmetirom plasma exposure, as documented in the FDA prescribing information [1]. That hepatic-transporter dependence matters here because 5-HTP and its downstream metabolite serotonin have documented effects on gut and hepatic serotonin signaling that can influence transporter expression [5].

What Is 5-HTP and Why Do People Take It?

5-HTP (5-hydroxytryptophan) is a naturally occurring amino acid and the direct metabolic precursor to serotonin (5-hydroxytryptamine, or 5-HT). The body synthesizes it from dietary tryptophan via tryptophan hydroxylase. Supplemental 5-HTP crosses the blood-brain barrier readily and raises central serotonin levels within hours of ingestion [6].

Common Uses

People use 5-HTP primarily for mood support, sleep quality, appetite suppression, and migraine prophylaxis. Doses in published trials range from 50 mg to 300 mg per day [7]. A 2002 Cochrane-adjacent systematic review found preliminary evidence for 5-HTP in depression, though the authors noted study quality limitations [8].

Why MASH Patients Often Reach for 5-HTP

Patients with MASH frequently experience fatigue, poor sleep, and depressive symptoms. A 2021 cross-sectional study found that depression prevalence among NAFLD/MASH patients reached 29%, roughly double the general-population rate [9]. That symptom burden drives many patients toward over-the-counter serotonin-support supplements, making the 5-HTP question especially common in this population.

How Does the Interaction Between 5-HTP and Resmetirom Work?

The interaction has two distinct components: one pharmacodynamic, one pharmacokinetic. Neither alone is well-studied for this specific pair, and no published randomized trial has examined them together. Applying mechanism-based reasoning and known data for each agent individually is therefore the correct clinical approach.

Pharmacodynamic Component: Serotonin Load

5-HTP raises serotonin in the gut, peripheral blood, and central nervous system [6]. Resmetirom itself is not a serotonergic drug. It does not inhibit serotonin reuptake, block serotonin receptors, or release serotonin. On its own, it poses no direct serotonergic risk.

The concern arises when a patient also takes a true serotonergic drug, such as an SSRI or SNRI, alongside 5-HTP. MASH patients have high rates of comorbid depression; a 2023 AASLD practice guidance document notes that clinicians should screen MASH patients for psychiatric comorbidities and initiate treatment when indicated [10]. That means many resmetirom patients may already be on an antidepressant, making the 5-HTP addition genuinely risky from a serotonin-syndrome standpoint.

Serotonin syndrome involves three overlapping mechanisms: excess serotonin synthesis (5-HTP contributes here), excess serotonin release, and reduced serotonin reuptake or breakdown. The classic triad includes neuromuscular abnormalities (clonus, hyperreflexia), autonomic instability (tachycardia, diaphoresis, hyperthermia), and altered mental status [11]. The FDA's MedWatch database contains case reports of serotonin syndrome involving 5-HTP combined with SSRIs, though exact incidence rates are difficult to quantify from spontaneous-reporting systems [12].

Pharmacokinetic Component: Hepatic Clearance in a Diseased Liver

Resmetirom is approved only for patients with fibrotic MASH, meaning the liver is already structurally abnormal. Hepatic fibrosis reduces functional hepatocyte mass and can decrease the activity of CYP2C8 and transporter proteins like OATP1B1 [13]. Reduced OATP1B1 activity, in particular, has been shown to raise plasma exposure of OATP1B substrate drugs by 40 to 200% in some pharmacokinetic studies [14].

Serotonin itself has been shown in animal models to inhibit hepatic OATP transporters at pharmacologically relevant concentrations [5]. If 5-HTP supplementation raises gut and portal serotonin substantially, there is a theoretical basis for reduced OATP1B-mediated hepatic uptake of resmetirom, which could raise systemic resmetirom exposure. This has not been confirmed in human pharmacokinetic studies, and the magnitude of any such effect in patients is unknown. It should be treated as a theoretical risk, not a confirmed one.

A Two-Axis Risk Framework for This Combination

Clinicians and patients can stratify risk along two axes when evaluating this combination:

Axis 1: Serotonergic co-medications. A patient taking resmetirom alone (no SSRI, SNRI, tramadol, linezolid, or triptans) faces minimal direct serotonergic risk from adding 5-HTP. The combination does not generate serotonin syndrome through resmetirom's mechanism. Adding 5-HTP to that scenario still warrants caution, but the pharmacodynamic risk is lower than in a patient with concurrent serotonergic medications.

Axis 2: Degree of hepatic fibrosis and drug-metabolizer status. A patient with F3 fibrosis who is a CYP2C8 poor metabolizer (approximately 1 to 6% of most populations) [15] faces a larger pharmacokinetic concern because resmetirom exposure is already elevated at baseline. Adding any agent that theoretically reduces hepatic transporter function compounds that exposure.

Patients who sit in the high-risk quadrant (concurrent serotonergic medication AND advanced fibrosis or poor metabolizer status) should avoid 5-HTP until a physician has explicitly reviewed the combination.

What Does Serotonin Syndrome Look Like, and When Is It an Emergency?

Serotonin syndrome exists on a spectrum. Mild cases produce restlessness, mild tremor, and loose stools. Moderate cases add hyperthermia (temperature above 38.5°C), diaphoresis, tachycardia above 100 beats per minute, and clonus. Severe cases can include temperature above 41°C, rhabdomyolysis, seizures, respiratory failure, and death [11].

Hunter Criteria for Diagnosis

The Hunter Serotonin Toxicity Criteria, published in the Quarterly Journal of Medicine, provide a clinical decision tool. A patient is classified as having serotonin toxicity if they have taken a serotonergic agent AND meet at least one of the following: spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor plus hyperreflexia, or hypertonia plus temperature above 38°C plus ocular or inducible clonus [11]. Sensitivity for severe toxicity using Hunter Criteria is approximately 84%, specificity approximately 97% [11].

If you develop any of those signs after starting 5-HTP alongside any serotonergic drug, stop both agents immediately and seek emergency care. Do not wait to see if symptoms resolve on their own.

Timeline of Serotonin Syndrome Onset

Most cases appear within 6 hours of a dose change or new addition to a serotonergic regimen [11]. That narrow window means symptoms that develop the morning after you start 5-HTP deserve immediate attention.

Resmetirom's Own Side-Effect Profile and How It Overlaps

The most common adverse effects of resmetirom in MAESTRO-NASH were nausea (25.6% at 120 mg vs. 12.6% placebo) and diarrhea (28.5% vs. 16.3%) [3]. Those GI symptoms overlap with early serotonin-syndrome presentation, which could mask or delay recognition of a 5-HTP-related adverse event. A patient who assumes nausea and loose stools are just "the Rezdiffra side effects" may not recognize that the addition of 5-HTP is pushing them toward a more serious problem.

The resmetirom prescribing information also notes transaminase elevations in a minority of patients [1]. 5-HTP at doses above 150 mg/day has been associated with eosinophilia-myalgia syndrome in contaminated batches, though that risk is tied to specific manufacturing impurities rather than the molecule itself [16].

Monitoring Plan If Your Physician Approves the Combination

Some patients will have a clinical justification for 5-HTP even while on resmetirom, particularly if mood and sleep symptoms are significant and non-serotonergic alternatives have not helped. If your prescriber reviews the full picture and decides the combination is acceptable, the following monitoring parameters are reasonable.

Lab Monitoring

• Liver enzymes (ALT, AST) at baseline and 4 weeks after adding 5-HTP, then every 3 months, because resmetirom already requires periodic liver monitoring per its prescribing information [1].
• A complete metabolic panel to assess renal function, which can be affected by rhabdomyolysis in severe serotonin syndrome.
• No specific serotonin blood level is clinically useful for monitoring; serotonin syndrome is a clinical diagnosis [11].

Symptom Monitoring

Keep a brief daily log for the first 4 weeks: heart rate on waking, bowel habit, any muscle twitching, and mood. Any new tachycardia (resting heart rate above 100 bpm), profuse sweating unrelated to ambient temperature, or muscle jerking warrants same-day contact with your care team.

Dose Considerations

If 5-HTP is approved, starting at the lowest reasonable dose (50 mg at bedtime) and waiting at least 2 weeks before any upward titration gives your physician time to observe your response. Doses above 150 mg/day appear to carry a higher incidence of GI adverse effects regardless of drug interactions [7].

What the Prescribing Information and Guidelines Say

The Rezdiffra FDA prescribing label (approved March 2024) does not list 5-HTP as a named interactant [1]. That is expected; the label focuses on CYP2C8 inhibitors (gemfibrozil, clopidogrel), OATP1B inhibitors (cyclosporine, rifampicin), and statin co-administration guidance. The absence of 5-HTP from the label does not mean the interaction is safe; it means it has not been specifically studied.

The American Association for the Study of Liver Diseases (AASLD) 2023 MASH Clinical Practice Guidance states: "Patients with MASH should be counseled that dietary supplements and herbal products may affect liver function and interact with pharmacologic therapies, and clinicians should take a complete supplement history at every visit" [10]. That guidance directly supports the recommendation to disclose 5-HTP use to your Rezdiffra prescriber.

The Natural Medicines database (formerly Natural Standard) classifies the 5-HTP and SSRI interaction as a "Major" concern based on additive serotonergic pharmacodynamics [17]. Because resmetirom patients often carry concurrent SSRI prescriptions, that Major rating is effectively applicable to many real-world resmetirom patients who add 5-HTP.

Alternatives to 5-HTP for MASH Patients Seeking Mood and Sleep Support

If the serotonergic concern makes 5-HTP unsuitable, several non-serotonergic options have evidence for mood and sleep in relevant populations.

Magnesium Glycinate

Magnesium deficiency is common in metabolic liver disease [18]. Oral magnesium glycinate (200 to 400 mg elemental magnesium at bedtime) has shown benefit for sleep-onset latency in small trials and poses no serotonergic risk. Magnesium has no known pharmacokinetic interaction with resmetirom's CYP2C8 or OATP1B pathways [19].

Melatonin

Melatonin 0.5 to 5 mg at bedtime is extensively studied for sleep-onset difficulty. A 2022 meta-analysis across 23 trials found melatonin reduced sleep-onset latency by a mean of 7.06 minutes and improved total sleep time [20]. Melatonin does not act on serotonin receptors directly. No pharmacokinetic interaction with resmetirom has been identified, though melatonin is primarily metabolized by CYP1A2, which is a different pathway [21].

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I remains the first-line intervention for chronic insomnia per the American Academy of Sleep Medicine [22]. It carries zero pharmacokinetic risk. A 2015 meta-analysis across 20 trials found CBT-I produced sleep-efficiency improvements of approximately 10 percentage points over control conditions [23].

Practical Steps Before You Start 5-HTP with Rezdiffra

1. List every prescription medication, OTC drug, and supplement you currently take and share that list with your resmetirom prescriber before adding 5-HTP.
2. Ask specifically whether you are on any serotonergic medication, including SSRIs, SNRIs, bupropion, tramadol, or triptans. If you are, 5-HTP requires a much more careful risk-benefit conversation.
3. Ask your prescriber to review your most recent liver-function tests and fibrosis staging. F3 fibrosis and CYP2C8 poor-metabolizer status both raise baseline resmetirom exposure and make any pharmacokinetic perturbation more clinically significant.
4. If approved, start at 50 mg/day of 5-HTP, taken at bedtime. Do not exceed 150 mg/day without explicit physician guidance.
5. Stop 5-HTP and contact your prescriber if you develop any two of the following within the first 6 hours of a new dose: rapid heart rate, muscle twitching, diarrhea, agitation, or excessive sweating.

The FDA MedWatch program accepts voluntary adverse event reports at fda.gov/safety/medwatch; if you suspect a supplement interaction caused harm, filing a report helps build the post-market safety database for future patients [12].